A longitudinal study of patients with lymphoma treated with CAR-T therapy has revealed a high frequency of neurotoxicity, underlining the need for neurological assessments of patients before and repeatedly after therapy infusions. The French researchers suggest the need for guidelines to improve early recognition of neurotoxicity and its management.